Objective To investigate the clinical effects and the quality of life of flupentixol-melitracen or paroxetine hydrochloride in treatment of the breast cancer patients with anxiety and depression after chemotherapy.Methods 135 breast cancer patients with anxiety and depression after chemotherapy were selected from November 2012 to January 2014 in the hospital.They were randomly divided into the treatment group ( n=68 ) and control group ( n =67 ).The control group were treated by paroxetine hydrochloride treatment, and the treatment group were treated by flupentixol-melitracen.The anxiety, depression and its impact on quality of life of patients were observed between two groups.Results After treatment, the HAMD score and HAMA score decreased significantly in two groups (P<0.05), HAMD score and HAMA score in treatment group after treatment significantly decreased compared with control group (P<0.05).After treatment, the WHOQOL-BREF score of mental health status scale of subjective feeling, the physiological domain, domain score levels in treatment group significantly increased (P<0.05), however, the quality of life of subjective feeling, social relationship and environment domains showed no significant difference.Compared with pre-treatment, only the health status of subjective feeling levels in control group post-treatment significantly increased (P<0.05).The mental health status scale of subjective feeling, the physiological domain, domain score levels in treatment group significantly decreased compared with control group ( P<0.05 ).The adverse reactions of treatment group were 5 cases (7.35%), which was significantly lower than 24 cases (35.82%) of control group(χ2 =16.22,P <0.05).Conclusion Flupentixol-melitracen combined with paroxetine hydrochloride has an obvious clinical effect in treatment of anxiety and depression in patients with breast cancer after chemotherapy.It could effectively control their anxiety and depression, and improve the quality of life of patients.It is worthy of clinical popularization and application.

Objective The objective of this study was to investigate the role of sulindac in sensitization effects of NF-κB on apoptosis induced by TNF-α in human breast cancer.Methods The human breast cancer MCF-7 cell line was added sulindal in the logarithmic growth phase and the final concentrations of sulindac were 0.5 and 1.0 mmol/L.The cells in control group was cultured without adding succinic acid.After sulindac treatment for 48 h,flow cytometry,MTT and Western blotting were used to analyze the effect and mechanism of cell growth in MCF-7 cells.Results The inhibitory rate of cell proliferation was(29.17±1.23)% and(38.15±1.51)% in MCF-7 cells treated with 0.5 and 1.0 mmol/L of Sulindac for 48 h,respectively,when compared to the control group(1.15 ± 0.02)%(P<0.05).Compared with the control group,0.5 and 1.0 mmol/L of sulindac were significantly increased the G0/G1 phase in MCF-7 cells(P<0.05).The apoptosis rate of sulindac in MCF-7 cells was significantly higher than that in the control group(P<0.05).The expression levels of TNF-α were(2.09±0.67)% and(1.18±0.09)% in the concentrations of 0.5 and 1.0mmol/L sulindac,respectively,in MCF-7 cells when compared to the control group(7.42±0.56)%.Conclusion Sulindac has a certain effect on the growth of human breast cancer cells,which can promote the prolongation of cell cycle at the G0/G1 phase and improve sensitization of apoptosis.This mechanism may be related to the inhibition of TNF-α activity.

Objective To explore clinical effect and life quality study of Shenyi capsule combined with docetaxel and cisplatin in treatment of advanced breast cancer.Methods 135 cases of advanced breast cancer of Huangshi Central Hospital were collected and diagnosed from July 2013 to December 2014 in accordance with the random number table,were divided into treatment group(n=69) and control group(n=66).Both groups were given regular basis treatment, control group was treated by docetaxel(75 mg/m2,twice a day)and cisplatin(25 mg/m2,once a day), and treatment group combined with Shenyi capsule(20 mg,twice a day)on the basis of control group treatment.4 weeks were 1 course, and all the cases were taken 12 weeks of continuous treatment.Observed and compared the clinical efficiency and life quality of two groups.Results The remission rate of 63.77% in treatment group was higher than control group of 40.91%, difference was statistically significant(χ2 =7.070,P=0.008).After treatment, the SF-36 scale in treatment group significantly increased from ( 54.69 ±8.78 ) to ( 63.87 ±12.08 ) , and higher than that of control group ( 57.95 ±11.95 ) , differences were statistically significant(P<0.05).The adverse reactions in treatment group was lower than control group, difference was statistically significant(Z=2.858,P =0.000).Conclusion The clinical effect in treatment of advanced breast canceris obvious by Shenyi capsule combined docetaxel and cisplatin.It can significantly improve clinical effect and life quality.

Objective To assess the role of E-cadherin (CDH1) promoter methylation in bladder carcinogenesis by meta-analysis. Methods The relevant database were searched by the retrieval strategy of Cochrane network. All included studies were collected following data:the first author’s surname, publication year of article, country, language of publication, design of study, sample size, ethnicity, histological subtypes, methylation detection method and genotype frequencies etc. This meta-analysis was performed using the STATA 12.0 software. The crude odds ratio (OR) with 95%confidence interval (CI) was calculated. Results Ten case-control studies were included in this meta-analysis. The methylation frequency of CDH1 was detected in 620 bladder cancer tissues and 341 normal or cancerous tissues. Results showed that the methylation frequency of CDH1 was significantly higher in bladder cancer tissue than that of normal or cancerous tissue (OR=3.09, 95%CI:1.13~8.50, P=0.029). Furthermore, the ethnicity-stratified analysis revealed that the methylation frequency of CDH1 was significantly higher in bladder cancer tissue of Asian populations than that of normal or cancerous tissue (OR=3.85, 95%CI:1.46~10.14, P=0.006), but no such association was found in Caucasian populations(OR=2.22, 95%CI:0.38-12.91, P=0.375). The subgroup analysis based on the detection methods revealed that there was a statistically significant difference in the methylation frequency of CDH1 between bladder cancer tissue and adjacent tissues and normal tissues under the MSP subgroup (P<0.001), while such association was not observed under the Q-MSP subgroup (P=0.818). Conclusion Pro?moter methylation of CDH1 gene may be involved in the occurrence and development of bladder cancer, which may serve as a biomarker for diagnosis and prognosis of bladder cancer.

Objective: To study whether the bond strength between enamel and composite resin could be enhanced by intraoral sand abrasive. Methods: Ten human maxillary first incisior teeth were divided into 2 groups The experimental group was sandblasted with 30 ?m Al 2O 3 (CoJet Sand, pressure 300 kPa) from a distance of 5 mm for 5 seconds, and the control group were not sandblasted. The Herculite composite resin composite cylinders were bonded with Coltene system. Bonded specimens were stored in 37 ℃ distilled water for 24 h, then were subjected to shear force in a testing machine Stress at failure was calculated in Mpa, and mode of failure was recorded. The Student t test was applied to the data. Results: The shear bond strength of experimental groups was (33.0?1.8) MPa , and that of control groups was (26.7?5.2) MPa ,there was significant difference between these two groups. All the adhesive failures happened at the enamel composite resin interface , except that cohesive failure happened in one sandblasted specimen. Conclusion: Intraoral sandblasting could significantly enhance the shear bond strength between enamel and composite resin.

Objecitve To study the inhibitory effect of pioglitazone on inflammation factors in patients with bladder cancer. Methods A total of 100 consecutives diagnosed as bladder cancer from Februray 2013 to Februray 2014 were individed ran-domly into experiment and control groups and each of 50 cases.All patients received the appropriate operation or chemother-apeutic regimens,and the patients in experiment group received pioglitazone (15 mg/d×12 weeks)at the same time.Then to compare expression differences of high-sensitive C reactive protein (hs-CRP),tumor necrosis factor alpha (TNF-alpha),in-terleukin (IL-6)and HOMA-IR,MCP-1,MIP-1 levels.Results The levels of hs-CRP,TNF-αand IL-6 in the two groups af-ter treatment were all lower (P <0.05),and in experiment groups they were significantly lower than control group (P <0.05).The levels of HOMA-IR,MCP-1 and MIP-1 in the two groups after treatment were all lower (P <0.05),and in ex-periment groups they were significantly lower than control group(P <0.05).The complication rate in the two groups were no statistical difference (P >0.05).Conclusion Pioglitazone could improve clinical effect and prognosis by lowing inflam-mation factors including hs-CRP,TNF-α,IL-6,HOMA-IR,MCP-1 and MIP-1 in patients with bladder cancer.

Objective To investigate the proliferation inhibition and the apoptosis induction effect of brucine on human chronic myeloid leukemia cell line HL-60 cells.Methods HL-60 cells were exposed to various dosages of brucine 24,48,72 h respectively,MTT method was used to assay the growth inhibition effect of brucine on HL-60 cells and the IC50 of brucine was evaluated at the same time.The morphology was observed by AO/EB stains.The cell apoptosis and cell cycle was tested by flow cytometry with Annexin V-FITC/PI double staining and PI labeling respectively.Results The results indicated that the brucine displayed significant anti-proliferative effect on HL-60 cells in a dose-and time-dependent manner,with IC50 value of 211.8 μg/ml(24 h),107 μg/ml(48 h),83 μg/ml(72 h)respectively.The most significant inhibition was observed at 320 μg/ml for 48 h.In this condition,apoptosis morphology was induced by brucine with nuclear chromatin condensation,most of the nuclears were orange stained and condensation-like or bead-like,which was consistent with the Annexin V-FITC/PI results.The cell apoptosis rates were(2.1±1.1)％,(21.3±1.2)％,(38.6±1.3)％,(58.5±4.1)％,(75.3±0.87)％and(66.2±0.75)％in different dose of brucine,respectively.At the same time,the cell cycle analysis results showed that the cell ratio in G0/G1 phase was decreased while in G2/M and sub-G0 phases was increased,comparing with blank control group.Conclusion Brucine can inhibit cell growth dramatically,which may be related to the cell apoptosis and the cell cycle arrest.

Phthaloyl dichloride (1)was reacted with LiAlSeH2 to give benzo[c]selenophene-1;3-dione (2);which was treated with the Grignard reagents to generate hydroxyl compounds 3a-3h.These compounds were finally converted to target products 4a-4h by treatment with hydriodic acid.The structures of 4a-4h were confirmed by MS and 1 H NMR.Their inhibitory activity against adenosine diphosphate (ADP)-induced platelet aggregation was evaluated by Born′s turbidimetric assay;free radical scavenging activity was assayed by xanthine oxidasemethod and 1;10-phenanthroline spectrophotometric method.It was found that compound 4 f displayed more potent inhibi-tory effect on platelet aggregation than 3-n-butylphthalide and comparable hydroxyl free radical scavenging activity in vitro to that of edaravone.Therefore;compound 4 f might be the candidate for further investigation.

Objective To study the Janus Kinase 2 V617F (JAK2V617F) point mutation in bcr-abl-negative myeloproliferative disorders (MPD) and explore its clinical significances. Methods Genomic DNA was isolated from bone marrow or peripheral-blood granulocytes. Allelespecific-polymerase chain reactions (AS-PCR), restriction enzyme digestion in combination with PCR product sequencing were performed to detect the mutation in genomic DNA. 110 patients were detected, including 41 with bcr-ablnegative MPD, 25 with bcr-abl-positive chronic myelogenous leukemia (CML), and 44 with acute leukemia.Results JAK2V617F was presented in 11 cases(91.7 %) of 12 polycythemia vera (PV), 8 cases(53.3 %) of 15 essential thrombocythemia(ET), 4 cases (57.1%) of 7 idiopathic myelofibrosis (IMF), while in other patients including 7 hypereosinophilic syndrome (HES), 25 bcr-abl-positive CML, 24 acute myelocytic leukemia (AML), 18 acute lymphoblastic leukemia(ALL), and 2 acute mixed lineage leukemia, JAK2V617F can not be detected. All positive samples and 10 negative samples identified by AS-PCR and restriction enzyme digestion were confirmed further by DNA sequencing. Conclusion The frequency of JAK2V617F mutation was more than 90 % among patients with PV, more than 50 % among patients with ET and IMF. The detection of JAK2V617F mutation will be of great significanees in the diagnosis and differential diagnosis of MPD. This mutation can be a molecular marker of MPD and might be a treatment target in the future.

BACKGROUND: In the past, guided tissue regeneration materials were produced by 13-tricalcium phosphate (β-TCP) and gelatin (Gel), but the production of fiber membrane by electro-spinning technique was reported less.OBJECTIVE: To prepare a new kind of Gel with β-TCP hybrid nanofibrous membrane and testing its biocompatibility compared with polylactic acid (PLLA) and poly(lactide-co-glycolide) (PLGA) membrane.METHODS: The β-TCP/Gel guided tissue regeneration membrane was made by electro-spinning technique.Scanning electron microscopy (SEM) was employed to observe membrane surface.MTT test was performed to compare toxicity among β-TCP/Gel,PLLA, and PLGA membranes.RESULTS AND CONCLUSION: The β-TCP/Gel membrane was porous, and β-TCP granules were nodosity-adhered on surface of Gel.The average diameter of fiber was 500-600 nm.The distribution of fiber ranged from 200 to 500 nm.There was no significant difference in toxicity among PLLA, PLGA, and negative control group (P > 0.05).The results suggested that the β-TCP /Gel membrane was low cytotoxicity and suitable for tissue engineering.It would be a promising material for periodontal tissue regeneration.